CRL vs. NBIX: Charles River Laboratories vs. Neurocrine Biosciences Stock Comparison

Company Profile

Charles River Laboratories (CRL) and Neurocrine Biosciences (NBIX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while NBIX is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Charles River Laboratories (CRL) has an aggressive beta of 1.33, indicating higher sensitivity to broad-market moves, while Neurocrine Biosciences (NBIX) is defensive at 0.29 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Neurocrine Biosciences (NBIX) at 20.42% sits in the top ROE quartile, while Charles River Laboratories (CRL) at 1.27% is closer to the peer norm — stronger capital efficiency for NBIX.

Neurocrine Biosciences (NBIX) at 18.98% converts revenue to bottom-line profit above its industry’s benchmark range, while Charles River Laboratories (CRL) at 1.01% keeps roughly the typical share for its industry.

Both Charles River Laboratories (CRL) at 23.42% and Neurocrine Biosciences (NBIX) at 31.98% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Neurocrine Biosciences (NBIX) at 21.45% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neurocrine Biosciences (NBIX) at 41.95% is around its peer norm for EPS growth, while Charles River Laboratories (CRL) at -1,555.00% falls below its industry range, a notably weak earnings reading.

Growth Metrics

Financial Strength

Both Charles River Laboratories (CRL) at 1.41 and Neurocrine Biosciences (NBIX) at 2.04 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Neurocrine Biosciences (NBIX) at 0.12 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Charles River Laboratories (CRL) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Charles River Laboratories (CRL) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Neurocrine Biosciences (NBIX) at 24.43 is near its industry’s usual P/E ratio, while Charles River Laboratories (CRL) at 366.87 sits above its peer range — an unusually expensive price for CRL’s trailing earnings.

On P/S ratio, both Charles River Laboratories (CRL) at 4.07 and Neurocrine Biosciences (NBIX) at 4.50 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Charles River Laboratories (CRL) at 5.01 and Neurocrine Biosciences (NBIX) at 4.30 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics